Antibody Therapies
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
202
NCT05143463
A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 4, 2021
Completion: Dec 22, 2022
NCT06249919
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Phase: Phase 1/2
Start: Jan 19, 2024
Completion: Jan 31, 2027
Loading map...